Beriplex P/N 1000 1240 Unit (Coagulation Factor Ix (Human) POWDER FOR SOLUTION) 1240 UNIT

BERIPLEX P/N 1000 1240 Unit is a coagulation factor IX (human) powder for solution, used for managing bleeding disorders. This intravenous medication supports blood clotting and is manufactured by CSL Behring Canada Inc.

Strength

1240 UNIT

Pack Size

50ML

Manufacturer / TM Owner

CSL BEHRING CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

BERIPLEX P/N 1000 1240 Unit is primarily used to manage bleeding episodes in individuals with coagulation disorders. It contains coagulation factor IX (human), which helps in blood clotting. This medication is often used for what is coagulation factor IX used for, including controlling bleeding in conditions like hemophilia B.

Side Effects

Common effects of BERIPLEX P/N 1000 1240 Unit may include localized reactions at the injection site, such as redness or swelling. Some individuals might experience mild allergic reactions. It is important to monitor for any unusual symptoms and consult a healthcare provider if they occur.

Precautions & Warnings

BERIPLEX P/N 1000 1240 Unit should be handled with care, ensuring proper storage and preparation. It is crucial to follow the instructions for intravenous administration to avoid complications. Individuals with known allergies to any components should exercise caution.

Avoid Interactions

BERIPLEX P/N 1000 1240 Unit may interact with other medications that affect blood clotting. It is important to inform healthcare providers about all current medications, including over-the-counter drugs and supplements, to avoid potential interactions.

Frequently Asked Questions

BERIPLEX P/N 1000 1240 Unit is used to manage bleeding episodes in individuals with coagulation disorders, such as hemophilia B.

BERIPLEX P/N 1000 1240 Unit is administered intravenously after reconstituting the powder with the provided solution.

Common side effects may include localized reactions at the injection site, such as redness or swelling.

It is important to consult a healthcare provider before using BERIPLEX P/N 1000 1240 Unit with other medications to avoid potential interactions.

BERIPLEX P/N 1000 1240 Unit should be stored as per the manufacturer's instructions to maintain its efficacy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.